PT  - JOURNAL ARTICLE
AU  - Pushkala, Subramanian
AU  - Seshayyan, Sudha
AU  - Theranirajan, Ethirajan
AU  - Sudhakar, Doraisamy
AU  - Raghavan, Kadalraja
AU  - Dedeepiya, Vidyasagar Devaprasad
AU  - Ikewaki, Nobunao
AU  - Iwasaki, Masaru
AU  - Preethy, Senthilkumar
AU  - Abraham, Samuel JK
TI  - Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective clinical trial
AID  - 10.1101/2021.12.14.21267778
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2021.12.14.21267778
4099  - http://medrxiv.org/content/early/2022/01/05/2021.12.14.21267778.short
4100  - http://medrxiv.org/content/early/2022/01/05/2021.12.14.21267778.full
AB  - Objective In this study, we evaluated the efficiency of the combination of two variants’ AFO-202 and N-163 strains of Aureobasidium Pullulans produced in comparison with the control arm, which underwent a conventional regimen of treatment alone, for a shorter duration of 15 days.Methods A total of 40 RT-PCR positive Covid-19 patients divided into two groups (Gr): Gr. 1 control (n=22) – Standard treatment; Gr. 2 (n =18) – Standard treatment + combination of AFO-202 and N-163 beta glucans for 15 days. Biomarkers of relevance to cytokine storm and coagulopathy were evaluated at baseline on Day 7 and Day 15.Results The C-reactive protein (CRP), which declined from 33.95 mg/l to 5.07 mg/l in control and from 33.95 mg/l to 5.64 mg/l in the treatment arm on Day 7, increased to 14.6 mg/l in the former while it continued to be under control in the treatment arm at 5.68 mg/l on Day 15. The same trend was observed in Ferritin, whose values were 560.58 ng/ml at baseline to 261.44 ng/ml (day-7) and 182.40 ng/ml (day-15) in the treatment group, while it was 535.24 ng/ml at baseline, 116.66 ng/ml on day 7 and 291.95 ng/ml on day 15 in the control group. IL-6 showed a higher decrease in treatment group compared to the control group. The difference between day 7 and day 15 values were statically significant.Conclusion A statistically significant control of IL-6, CRP and Ferritin in Covid-19 patients who orally consumed AFO-202 and N-163 strains of Aureobasidium Pullulans produced Beta glucans together in 15 days make us recommend this safe food supplement be consumed by Covid-19 patients along with conventional treatments, especially to the vulnerable population, as a prophylaxis amidst the prolonged pandemic with evolution of mutated strains of SARS-COV2.Competing Interest StatementAuthor Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.Clinical TrialThe study was registered in Clinical trials registry of India, CTRI/2021/10/037380Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Committee (IEC) of Madras Medical College, India on 15th September, 2021.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript